Qualigen Therapeutics Inc (QLGN) USD0.001
Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.